SCHEMBL31128462

SCHEMBL31128462

COC(=O)C1CC(CCCOCc2ccccc2)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.46
ALDH1A1 P00352 2/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CPB1 P15086 1/20 0.44
NAAA Q02083 1/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
AGTR2 P50052 1/20 0.41
LTA4H P09960 1/20 0.41
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP1A2 P05177 1/20 0.40
POLB P06746 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
TSHR P16473 1/20 0.40
TEAD3 Q99594 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31128457 1.00 EPHX2 (0.46) EPHX2ALDH1A1MAPTHPGDNPSR1
SCHEMBL21801247 0.80 ALDH1A1 (0.42) EPHX2ALDH1A1MAPTHPGDNPSR1
SCHEMBL17891790 0.79 AGTR2 (0.46) ALDH1A1MAPTNPSR1HSD17B10AGTR2
SCHEMBL17891789 0.79 AGTR2 (0.46) ALDH1A1MAPTNPSR1HSD17B10AGTR2
SCHEMBL6019299 0.78 ALDH1A1 (0.46) EPHX2ALDH1A1MAPTHPGDNPSR1
SCHEMBL28840618 0.78 ALDH1A1 (0.43) ALDH1A1MAPTHPGDNPSR1HSD17B10
SCHEMBL6018931 0.78 ALDH1A1 (0.46) EPHX2ALDH1A1MAPTHPGDNPSR1
SCHEMBL6018928 0.78 ALDH1A1 (0.46) EPHX2ALDH1A1MAPTHPGDNPSR1
SCHEMBL17891866 0.77 AGTR2 (0.54) EPHX2ALDH1A1RAB9ANPC1AGTR2
SCHEMBL17891864 0.77 AGTR2 (0.54) EPHX2ALDH1A1RAB9ANPC1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024165831-A1 IMIDAZOLIDONE AND SUCCINIMIDE DERIVATIVES FOR USE AS ALPHA V BETA 3 INTEGRIN INHIBITORS FOR THE TREATMENT OF CANCER UNIVERSITY OF BRADFORD (GB) 2024-08-15 WO disclosed